InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
17,034.40
(
1.03%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.95
(
0.48%
)
Bitcoin
58,244.77
(
0.01%
)
Post# of 251673
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Mufaso post# 246303

Wednesday, 07/26/2023 5:38:25 PM

Wednesday, July 26, 2023 5:38:25 PM

Post# of 251673
VKTX’s oral formulation of VK2735 is expected to have at best ~60% of the weight-loss efficacy of the injected formulation, according to VKTX’s 2Q23 CC today.

The oral formulation may also have a fasting requirement. When asked about this on the CC, management said this detail has not been disclosed, which implies that there is or may be a fasting requirement. (If there were definitely no fasting requirement, management would presumably have said so.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up